The hormone receptor status of breast tumours is used to determine treatment strategies and to predict overaHl survival. In addition to oestrogen (ER) and progesterone (PR) receptors. the androgen receptor (AR) is frequently expressed in hormoneresponsive tumours. Immunohistochemical studies have demonstrated that at least 801% of primary breast cancers contain AR-positive tumour cells (Kuenen-Boumeester et al. 1992 : Isola. 1993 : Hall et al. 1996 . Moreover. AR is expressed in 25% of breast tumour metastases in the absence of ER and PR (Lea et al. 1989) . Recently. we reported that the AR concentration in primary breast tumours is predictive of treatment response to medroxyprogesterone acetate. a synthetic progestin with both progestin and androgenic activity (Birrell et al, 1995) .
Prostate-specific antigen (PSA: hKLK3) is a member of the human kallikrein gene family (Clements. 1994) and is an androgen-regulated serine protease secreted by the prostate (Lilja. 1985 : Henttu et al. 1992 . PSA is widely used as a serum marker for the detection of early-stage prostate cancer and monitoring disease progression (Oesterling. 1991) . PSA is also expressed in other tissues Yu. 1995. 1997) including pituitary (Clements et al. 1996) . endometrium (Clements and Mukhtar. 1994 ) and apocrine foci in benign breast disease (Papotti et al. 1989 : Howarth et al. 1997 ). In addition. PSA is present in amniotic fluid (Melegos et al. 1996) . breast milk and breast cyst fluid
Received 25 September 1997 Revised 23 Decemrber 1997
Accepted 16 January 1998 Correspondence to. RE Hall (Mannello et al. 1996) . The reported incidence of immunoreactive PSA in breast tumours varies from 15% to 70% : Wu et al. 1995 : Ferguson et al. 1996 . PSA has also been demonstrated in ovarian (Yu et al. 1995a ) and renal (Pummer et al. 1992 : Clements et al. 1997 tumours. PSA secretion is stimulated by progesterone, glucocorticoids and mineralocorticoids. in addition to androgens. but not by oestradiol. in T-47D human breast cancer cells (Zarghami et al. 1997) . The primary substrates for PSA are semenogelin and fibronectin. a reaction that leads to dissolution of the seminal clot (Lilja et al. 1987) . In vitro studies suggest that other substrates for PSA include parathyroid hormone-related peptide (Iwamura et al. 1996) and insulin-like growth factor binding protein-3 (Cohen et al. 1992) . PSA also degrades the extracellular matrix proteins. fibronectin and laminin. and hence may facilitate prostate tumour invasiveness (Webber et al. 1995) . suggesting that PSA expression in breast tumours may be a marker of disease progression. However, the presence of PSA in breast tumours has been associated with favourable prognostic markers. e.g. PR-positive tumours . early-stage disease. small tumour size and ER-positive tumours (Yu et al. 1995b ). Furthermore. a higher concentration of PSA in cytosolic extracts of primary breast tumours was associated with reduced relative risks for relapse and death (Yu et al. 1997) .
Gross cystic disease fluid protein-15 (GCDFP-15). also known as secretory actin-binding protein (Schenkels et al. 1994) . is present in approximately 50% of all breast carcinomas and, like AR and PSA. the presence of GCDFP-15 is frequently associated with apocrine features (Haagensen Jr. 1991 (Schenkels et al. 1994) and to CD4 domains on T lymphocytes (Autiero et al. 1995) . which has led to the suggestion that GCDFP-15 may modulate tumour invasiveness (Autiero et al. 1995) . Although women with breast cystic disease have an increased risk of subsequently developing breast cancer (Haagensen Jr. 1991 : Haagensen et al. 1997 . the presence of GCDFP-15 in breast tumours has been associated with ER content (Murphy et al. 1987 ) and a longer relapse-free sur ival (Pagani et al. 1994) .
Androgens regulate the synthesis and secretion of both PSA (Zarghami et al. 1997 ) and GCDFP-15 (Myal et al. 1991) in T47D human breast cancer cells. Therefore. in the present study we examined both PSA and GCDFP-15 immunoreactivity in relation to AR immunoreactivity in primary breast tumours.
British Joumal of Cancer (1998) (Hall et al. 1996) : PSA. 1:1000 and GCDFP-15. 1:5000 (Mazoujian et al. 1983) . AR was detected followinmg microwave retrieval. as reported previously (Hall et al. 1996 Figure 1B ). Immunoreactive PSA was also localized in the cytoplasm of tumour cells ( Figure IC ) and was present extracellularly in ductal luminae. Only a few breast tumours showed widespread staining for PSA ( Figure IC) . whereas the majority of PSA-positive tumours showed focal PSA immunoreactivity ( Figure ID and E (Figure 2 ). AR immunoreactivitv was significantly associated with the presence of both ER (P < 0.05) and PR (P < 0.01) in primary breast tumours (Table 1) .
ER and PR positivitv were also significantly associated (P < 0.001). associated with both PSA (P < 0.001) and GCDFP-15 (P < 0.05) immunostaining ( Other studies. including those from our laboratori (Abrahamsson et al. 1988 : Aspinall et al. 1995 : Zhang et al. 1998 (Yu et al. 1995b) or PR . or both ER and PR positivity in breast tumour cytosols (Ferguson et al. 1996) . no significant associations were found between PSA and ER or PR status in the present study (Table 4) . Importantly. one of the previous studies identified that PSA positivity was significantly associated with PR and not with ER in subsets of breast tumours (viz. ER + PR +: ER -PR +) . The failure to detect a direct association between PSA and PR in our study was possibly due to the relatively small number of cases (72) (Birrell et al. 1995) . indicating the potential usefulness of AR as a prognostic marker. In the present study. we have shown that. although AR. ER and PR are co-expressed in breast tumours. PSA and GCDFP-15 positivitv is significantly associated with AR alone and not determined by ER or PR status of the primary tumour. The data from this and previous studies suggest that the expression of PSA and GCDFP-15 may be dependent on a functional AR pathway. This study also demonstrates that immunoreactive PSA. like (Haagensen Jr. 1991) . is strongly associated with the presence of AR in primary breast tumours. suggesting that both PSA and GCDFP-15 are androgen-regulated in breast tumours in vivo. In conclusion. although it has been suggested that PSA and 
